AID Genomics is focused on delivering advanced diagnostics solutions to facilitate better preventative strategies for healthy individuals and more personalized treatment strategies for individuals battling cancer. By combining bioinformatics with next-generation sequencing and artificial intelligence, AID Genomics seeks to operate at the vanguard of precision medicine by unlocking the secrets hidden within DNA. AID also focuses on infectious diseases and has sales offices in Japan, US, and other Asian countries. In 2020 our expertise was recognized by the Israeli government and was chosen by its MOH & MOD to build, operate, and maintain seven dedicated Covid-19 tests laboratories with a current capacity of 100,000 tests per day. The majority shareholder of AID Genomics Limited is A.I.D. Partners, an investment group founded in 2007 in Hong Kong and Chairman Mr. Kelvin Wu. It has managed over US$1.5 billion assets in Media, IT and Healthcare since its inception. Our other shareholder, www.Wilab.com, is one of the leading VCs in Japan.